Accelerating Actionable Innovation
We are continuously building on a legacy of excellence, expertise and achievement in viral vector delivery. Born out of world renowned research from the Mayo Clinic, our team of leading experts in cell-specific targeting, virus therapy, and oncology drug development are creating targeted viral delivery solutions that make in vivo gene therapies possible. We are collapsing the timeline for in vivo CAR T treatments, creating practical, off-the-shelf solutions that fundamentally change how these life-saving therapies are delivered.
Novel G protein targeting methods
Our in vivo platforms are distinguished by their innovative approaches to G protein engineering. Utilizing either retargeted VSV-G or a novel adapter peptide system, our process simultaneously masks the lentiviral vector’s native receptors, while also displaying targeting ligands that guide the vector with high target specificity. Designed to preserve the G protein’s natural, potent fusion function, these approaches result in viral vector delivery that achieves high serum stability and enhanced transduction efficiency for precision in vivo gene delivery.
Leveraging a Targeted Approach
A combination of an innovative approach to novel engineering of targeted vectors and decades of expertise across virus families allows us to develop and de-risk the appropriate delivery platform for targeted in vivo genetic therapies.
Partnering for Targeted Therapies
Our novel delivery platforms make in vivo gene therapies possible. Now, we are looking to forge partnerships with in vivo gene therapy and genome editing therapeutic developers to realize that potential with us.
For each program we can work collaboratively to:
